Wordt geladen...
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
The paradigm for managing patients with chronic myeloid leukemia is evolving. In the recent past, restoring a normal life expectancy while patients are receiving never-ending targeted therapy with BCR–ABL1 tyrosine kinase inhibitors through prevention of progression to blast phase and mitigation of...
Bewaard in:
| Gepubliceerd in: | Blood Adv |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7656932/ https://ncbi.nlm.nih.gov/pubmed/33170936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002538 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|